|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CDR1as inhibition in vivo also induced tumor regression with decreased PCNA levels, and miR-7 inhibitor could reverse these effects via upregulation of <i>EGFR</i>, <i>CCNE1</i>, <i>PI3KCD</i>, and <i>RAF1</i>.
|
30425578 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
When the epithelium invaded the lamina propria and well-differentiated OSCC began, the p75<sup>NTR</sup>-positive cell frequency drastically decreased in epithelial cords and nests, showing a negative correlation with PCNA expression. p75<sup>NTR</sup> immunolabeling during 4-NQO-induced carcinogenesis was similar to that described for human head and neck dysplasia and neoplasia.
|
30268558 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Eight weeks after tumor cell inoculation, immunohistochemistry was used to assess the therapeutic efficacy according to microvessel density (MVD), proliferating cell nuclear antigen (PCNA), and terminal-deoxynucleotidyl transferase-mediated nick-end labeling (TUNEL) assays.
|
29659181 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These peptides/proteins play an important role in regulating tumor energy metabolism, epithelial to mesenchymal transition of cancer cells, the stability of the c-Myc oncoprotein, and the ubiquitination and degradation of proliferating cell nuclear antigen (PCNA).
|
30483132 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cyclin-D kinase 4/6 inhibitors (CDK4/6i) can halt tumor proliferation by blocking the ER related transcription signaling that drives the CDK4/6-dependent cell cycle in HR+ tumors, and they work best together with AI or SERD.
|
30105234 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
<sup>131</sup>I-5-IPN treatment was associated with reduction of expression of proliferating cell nuclear antigen (PCNA) and Ki67 and cell cycle blockage in G2/M phase in tumor tissues.
|
30537980 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of PCNA is dysregulated in some tumors and takes part in the progression of oncogenesis.
|
29803172 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Compared with the model group, QD showed inhibition of proliferation of LLC cells and reductions in tumor weight and proliferating cell nuclear antigen protein expression.
|
28617188 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A cell-permeable peptide harboring the L126-Y133 sequence blocked PCNA interaction in cancer cells and selectively kills cancer cells and xenograft tumors.
|
29967249 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tumor proliferation marker PCNA was reduced by inotodiol.
|
29331760 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Nude mouse xenograft model was undertaken with HeLa cells and the xenograft tumor tissue samples were analyzed for the expression of PCNA and Ki‑67 by immunohistochemistry and the cell morphology was evaluated by hematoxylin and eosin (H&E).
|
29328485 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Such drug-mediated cyclin E induction in TNBC cells and PDX models sensitizes them to AZD1775 in a sequential treatment combination strategy.<b>Conclusions:</b> Cyclin E is a potential biomarker of response (i) for AZD1775 as monotherapy in cyclin E-high TNBC tumors and (ii) for sequential combination therapy with CDK2 inhibitor or carboplatin followed by AZD1775 in cyclin E-low TNBC tumors.
|
30181387 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The ratio of <sup>18</sup> F-FLT uptake for H460 and A549 tumors was 3.32 ± 0.17 and 1.48 ± 0.09 (P < 0.05), and there was more Ki-67 and PCNA in H460 tumor than A549.
|
29756310 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Higher levels of cell cycle markers were associated with higher WHO grade tumors and correlations between the markers suggested formation of cyclin/CDK activated complexes in S and G2/M phases.
|
29331723 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The results showed that NP-Pt treatment of U87 and U118 glioma cells decreased the level of DNA synthesis and the migration of cancer cells but also downregulated the level of PCNA protein expression in tumour tissue.
|
28562655 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cyclin-dependent kinases (CDKs) are closely associated with gene regulation in tumour biology.
|
29022909 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemistry analysis of proliferating cell nuclear antigen and vascular endothelial growth factor also revealed that SCB inhibited cell proliferation and metastasis in NSCLC xenograft tumors.
|
28259903 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
G9a depletion suppresses xenograft tumor growth in mouse model, which is linked to a decrease in microvessel density and proliferating cell nuclear antigen expression.
|
28977928 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Further in vivo tumor formation study in nude mice indicated that inhibition of <i>CTNNB1</i> delayed the progress of tumor formation through inhibiting PCNA and Ki67 expression.
|
28260916 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Di(2-ethylhexyl)phthalate (DEHP) may cause carcinogenicity in the liver; however, few have detailed on the potential effects of DEHP exposure on colorectal cancer.Male Sprague-Dawley rats received i.p. injections of 1,2-dimethylhydrazine (DMH) once-a-week for the first 4 weeks, and rats in each group were treated with DEHP through oral gavage daily for either 7, 10 or 15 weeks; after which, all rats were euthanized and their colons were assessed (a) morphologically for aberrant crypt foci (ACF) or tumors, (b) cytologically for mitotic index (MI), and (c) immunohistochemically for the expression of β-catenin, cyclooygenase (COX)-2, vascular endothelial growth factor (VEGF), proliferating cell nuclear antigen (PCNA), cyclin D1, and c-myc.
|
28284729 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, silencing HIWI2 in Y79 accumulated the cells at G2-M phase and reduced the levels of proliferating cell nuclear antigen (PCNA) and the tumor suppressor, p16.
|
28861107 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Histopathological examination of tumor tissues showed that PCNA expression was significantly decreased, while TUNEL-stained cells were markedly increased in the IT Pa-PDT group compared to controls.
|
27629775 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Paraffin sections from xenograft tumor specimens were used in the TUNEL (terminal deocynucleotide transferase dUTP nick end labeling) assay and an immunohistochemistry assay to detect cell proliferation markers Ki67 and PCNA.
|
27151584 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, targeting FAN1 activities and its interaction with ubiquitylated PCNA may offer therapeutic opportunities for treatment of BRCA-deficient tumors.
|
29051491 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The results showed that the immunohistochemical Proliferating Cell Nuclear Antigen (PCNA) labeling indexes (PCNA LI%) were significantly inhibited in liver tissues and tumors by both treatments of GSPE.
|
28747012 |
2017 |